Logo do repositório
 
Miniatura indisponível
Publicação

Can enzyme replacement therapy revert¨iNKT¨cell dysfunction in acid sphingomyelinase deficiency patients?

Utilize este identificador para referenciar este registo.
Nome:Descrição:Tamanho:Formato: 
OC FM SPDM.pdf159.39 KBAdobe PDF Ver/Abrir

Orientador(es)

Resumo(s)

Acid sphingomyelinase deficiency (ASMD) is a lysosomal storage disease caused by deficient activity of the enzyme acid sphingomyelinase (ASM), resulting in an abnormal accumulation of sphingomyelin in lysosomes. The abnormal accumulation of sphingomyelin, a crucial cell membrane component, ultimately impairs pulmonary, hepatic, and sometimes neurological functions, with severe forms of the disease being fatal in the first years of life. Invariant Natural Killer T (iNKT) cells are lipid-reactive T cells that play a central role in a wide range of immune responses including cancer, infection and inflammation. iNKT cells are restricted to CD1d, depending on the presentation of lipids by this molecule for their function. Sphingomyelin is a lipid with affinity for CD1d and its accumulation in ASMD influences the role of iNKT cells by impairing normal lipid antigen presentation to these cells. Interestingly, ASM-/- mice have reduced number of iNKT cells and impaired iNKT cell activity, in ASMD patients a reduced frequency of iNKT cells is also observed (1). Noteworthy, enzyme replacement therapy (ERT) with recombinant ASM can prevent iNKT cell deficiency in ASM-/- mice (1). In the current study we are investigating the effect of ERT on iNKT cells in ASMD adult patients.

Descrição

Palavras-chave

Acid Sphingomyelinase Deficiency (ASMD) Acid Sphingomyelinase (ASM) Lysosomal Storage Disease iNKT Doenças Genéticas

Contexto Educativo

Citação

Projetos de investigação

Unidades organizacionais

Fascículo

Editora

Licença CC

Sem licença CC